PMC

(A) Evaluation of ROS-induced eNOS suppression.NTN, normotension; HTN, hypertension; NTN+OGD, normotension+OGD; HTN+OGD, hypertension+OGD. Results are presented as means ± SEM (###p < 0.001 compared with the NTN group; **p< 0.01 compared with the HTN group; ++p< 0.01 compared with the NTN+OGD group). (B)Preventive effects of linalyl acetate on ROS-induced eNOS suppression. HTN+OGD+LA25, hypertension+OGD+25 mg/kg linalyl acetate; HTN+OGD+LA50, hypertension+OGD+50mg/kg linalyl acetate; HTN+OGD+LA100, hypertension+OGD+100 mg/kg linalyl acetate; HTN+OGD+A, hypertension+OGD+15 mg/kg ASA. Results are presented as means ± SEM (*p < 0.05,***p < 0.001 compared with the HTN+OGD group; ##p< 0.01, ### p < 0.001 compared with the HTN+OGD+LA25 group; +p < 0.05 compared with the HTN+OGD+LA50 group).

(A) Evaluation of p47phox expression levels after hypertension and OGD/R exposure. NTN, normotension; HTN, hypertension; NTN+OGD, normotension+ OGD; HTN+OGD, hypertension + OGD. Results are presented as means ± SEM (#p< 0.05, ## p< 0.01 compared with the NTN group; *p< 0.05 compared with the HTN group).(B) Inhibitory effects of linalyl acetate on p47phox expression in the HTN+OGD group. HTN+OGD+LA25, hypertension+OGD+25 mg/kg linalyl acetate; HTN+OGD+LA50, hypertension+OGD+50 mg/kg linalyl acetate; HTN+OGD+LA100, hypertension+OGD+100 mg/kg linalyl acetate; HTN+OGD+ A, hypertension+OGD+15 mg/kg ASA. Results are presented as means ± SEM (**p< 0.01, ***p < 0.001 compared with the HTN+OGD group; # p< 0.01 compared with the HTN+OGD+LA25 group).

(A) Evaluation of injury-induced ROS production and (B) LDH release after hypertension and OGD/R exposure. NTN, normotension; HTN, hypertension; NTN+OGD, normotension + OGD; HTN+OGD, hypertension + OGD. Results are presented as means ± SEM (#p< 0.05, ### p < 0.001 compared with the NTN group; *p < 0.05 compared with the HTN group). (C) Inhibitory effects of linalyl acetate on ischemic injury-induced ROS production and (D) LDH release in the HTN+OGD group. HTN+OGD+LA25, hypertension+OGD+25 mg/kg linalyl acetate; HTN+OGD+LA50, hypertension+OGD+50 mg/kg linalyl acetate; HTN+OGD+LA100, hypertension+OGD+100 mg/kg linalyl acetate; HTN+OGD+A, hypertension+OGD+15 mg/kg ASA. Results are presented as means ± SEM (*p < 0.05, **p < 0.01, ***p< 0.001 compared with the HTN+OGD group; #p < 0.05 compared with the HTN+OGD+LA25 group; ++ p < 0.01, +++p < 0.001 compared with the HTN+OGD+LA50 group; $ $ $p < 0.001 compared with the HTN+OGD+LA100 group).

Differences in (A) SBP and (B) DBP among groups on day 22 after linalyl acetate or PEG injection. Results are presented as means ± SEM (#p< 0.05, ## p < 0.01, ### p < 0.001 compared with the normotensive group; ** p< 0.01 compared with the hypertensive group; + p< 0.01 compared with the hypertension + 25 mg/kg linalyl acetate group). NTN, normotension; HTN, hypertension; HTN+LA25, hypertension+25 mg/kg linalyl acetate; HTN+LA50, hypertension+50 mg/kg linalyl acetate; HTN+LA100, hypertension+100 mg/kg linalyl acetate, HTN+A, hypertension+15 mg/kg ASA.